Cytokinetics, Incorporated Share Price & Technical Analysis
CYTK · $76.94 (-1.43%)
Healthcare / Biotechnology
$76.94
-1.43%
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral,…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
20% return in May, -16% avg return in past 3 year May month.
23% return in 2026, 30% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 0% | 0% | 7% | -4% | 20% | – | – | – | – | – | – | – | 23% |
| 25 | 3% | -5% | -13% | 6% | -28% | 6% | 14% | -6% | 22% | 15% | 7% | -6% | 17% |
| 24 | -7% | -8% | -4% | -12% | -21% | 12% | 10% | -3% | -7% | -3% | 1% | -7% | -51% |
| 23 | -8% | 2% | -19% | 6% | 1% | -14% | 3% | 5% | -16% | 19% | -4% | 149% | 125% |
| 22 | -27% | 6% | 4% | 8% | 0% | -2% | 0% | 26% | -8% | -13% | -3% | 9% | -2% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Strong · Strong
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$10.13B
P/E ratio
—
52W high
$80.20
52W low
$29.81
Volume
11,11,298
Beta
0.38
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Cytokinetics, Incorporated share price today?
- Cytokinetics, Incorporated (CYTK) last traded around $76.94 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does CYTK have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for CYTK. Download the app for real-time alerts.
- How can I analyze Cytokinetics, Incorporated stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.